# Estonia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Estonia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Estonia (EST)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $126.4M
- Products: 37
- Buyer markets: 29
- Average CAGR: +30.4%
- Global sector size: $668.7B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $276.0B | $27.2M | $106.5B | +10.0% | 18 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $159.7B | $3.1M | $65.9B | +22.3% | 16 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $19.4B | $2.8K | $33.8B | -22.9% | 3 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $19.8B | $18.9K | $28.4B | +43.8% | 2 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $30.5B | $1.3M | $17.3B | +20.5% | 7 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.1B | $3.7M | $17.2B | +24.4% | 8 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $21.5K | $15.5B | +124.8% | 2 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.1B | $15.9K | $14.5B | +26.8% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $9.4K | $7.4B | -1.8% | 2 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.5B | $6.6K | $7.1B | -5.3% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $115.2K | $7.0B | +20.6% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $1.3M | $6.3B | +13.4% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $8.5B | $604.8K | $6.2B | +7.2% | 4 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.9B | $148.3K | $5.1B | +24.0% | 2 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $72.6 | $4.8B | -26.1% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.0B | $21.4K | $4.4B | +423.2% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $27.1K | $4.1B | -10.2% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $18.4K | $3.3B | +1.5% | 2 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.6B | $164.4 | $3.1B | -22.5% | 1 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $3.2B | $246.7K | $2.4B | +20.4% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $621.9 | $2.4B | +33.6% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $65.2K | $1.9B | +74.8% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $666.9K | $1.8B | -20.0% | 1 | +0.1% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $493.0 | $1.8B | -15.7% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.7B | $31.5K | $1.7B | -0.3% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $1.4B | $51.8K | $1.7B | +52.2% | 1 | +0.0% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $4.2M | $1.5B | +14.1% | 1 | +0.3% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $7.3 | $1.4B | -7.2% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $1.3K | $1.4B | -3.3% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $327.5K | $1.3B | +347.7% | 1 | +0.4% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $349.8K | $1.3B | +11.0% | 1 | +0.0% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $82.8M | $1.2B | +259.1% | 1 | +2.6% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $1.3K | $1.2B | +77.1% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $434.5 | $1.1B | -29.3% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $34.1 | $1.1B | -44.4% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $7.2K | $1.1B | +37.0% | 1 | +0.0% |
| HS 290250 - Cyclic hydrocarbons: styrene | $768.8M | $3.4K | $1.1B | +86.9% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $124.9B calculated opportunity across 13 products.
- Slovenia (SVN): $38.9B calculated opportunity across 6 products.
- Germany (DEU): $37.2B calculated opportunity across 11 products.
- Switzerland, Liechtenstein (CHE): $33.9B calculated opportunity across 3 products.
- China (CHN): $21.8B calculated opportunity across 9 products.
- Netherlands (NLD): $20.7B calculated opportunity across 6 products.
- Belgium (BEL): $12.6B calculated opportunity across 3 products.
- Italy (ITA): $12.1B calculated opportunity across 3 products.
- United Kingdom (GBR): $10.7B calculated opportunity across 5 products.
- Spain (ESP): $9.0B calculated opportunity across 4 products.
- Canada (CAN): $8.0B calculated opportunity across 4 products.
- Mexico (MEX): $7.0B calculated opportunity across 4 products.

## Growth stars

- HS 290919: +423.2% average CAGR, $4.4B calculated opportunity.
- HS 310221: +347.7% average CAGR, $1.3B calculated opportunity.
- HS 310530: +259.1% average CAGR, $1.2B calculated opportunity.
- HS 293399: +124.8% average CAGR, $15.5B calculated opportunity.
- HS 290250: +86.9% average CAGR, $1.1B calculated opportunity.
- HS 293339: +77.1% average CAGR, $1.2B calculated opportunity.
- HS 382319: +74.8% average CAGR, $1.9B calculated opportunity.
- HS 381512: +52.2% average CAGR, $1.7B calculated opportunity.
- HS 300214: +43.8% average CAGR, $28.4B calculated opportunity.
- HS 321590: +37.0% average CAGR, $1.1B calculated opportunity.

## Diversification opportunities

- HS 300490: 18 buyer markets, $106.5B calculated opportunity.
- HS 300215: 16 buyer markets, $65.9B calculated opportunity.
- HS 382499: 8 buyer markets, $17.2B calculated opportunity.
- HS 300212: 7 buyer markets, $17.3B calculated opportunity.
- HS 300439: 4 buyer markets, $6.2B calculated opportunity.
- HS 293719: 3 buyer markets, $33.8B calculated opportunity.
- HS 330499: 3 buyer markets, $7.0B calculated opportunity.
- HS 382200: 3 buyer markets, $6.3B calculated opportunity.
- HS 300214: 2 buyer markets, $28.4B calculated opportunity.
- HS 293399: 2 buyer markets, $15.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.